Connor, Clark & Lunn Investment Management Ltd. Jounce Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.9 - $1.85 $13,863 - $28,497	15,404 New	15,404 $28,000
Q3 2022 Nov 10, 2022	BUY	$2.73 - $4.92 $51,356 - $92,555	18,812 Added 14.92%	144,885 $339,000
Q2 2022 Aug 05, 2022	SELL	$2.8 - $7.67 $126,142 - $345,541	-45,051 Reduced 26.33%	126,073 $382,000
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $21,720 - $30,863	-3,614 Reduced 2.07%	171,124 $1.16 Million
Q4 2021 Feb 10, 2022	BUY	$7.11 - $9.64 $382,802 - $519,017	53,840 Added 44.53%	174,738 $1.46 Million
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $243,442 - $421,676	48,302 Added 66.54%	120,898 $898,000
Q2 2021 Aug 12, 2021	SELL	$6.58 - $10.66 $82,901 - $134,305	-12,599 Reduced 14.79%	72,596 $494,000
Q1 2021 May 13, 2021	SELL	$6.73 - $13.87 $65,509 - $135,010	-9,734 Reduced 10.25%	85,195 $875,000
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $34,761 - $56,370	-5,457 Reduced 5.44%	94,929 $665,000
Q3 2020 Nov 12, 2020	SELL	$4.58 - $10.95 $362,635 - $866,999	-79,178 Reduced 44.09%	100,386 $819,000
Q2 2020 Aug 13, 2020	SELL	$4.17 - $7.58 $18,865 - $34,291	-4,524 Reduced 2.46%	179,564 $1.24 Million
Q1 2020 May 13, 2020	SELL	$2.91 - $8.7 $6,984 - $20,880	-2,400 Reduced 1.29%	184,088 $874,000
Q4 2019 Feb 12, 2020	SELL	$2.81 - $9.21 $4,777 - $15,657	-1,700 Reduced 0.9%	186,488 $1.63 Million
Q3 2019 Nov 13, 2019	BUY	$3.33 - $4.93 $40,126 - $59,406	12,050 Added 6.84%	188,188 $627,000
Q2 2019 Aug 07, 2019	SELL	$4.3 - $6.73 $34,830 - $54,513	-8,100 Reduced 4.4%	176,138 $872,000
Q1 2019 May 08, 2019	BUY	$3.43 - $6.87 $54,633 - $109,425	15,928 Added 9.46%	184,238 $1.14 Million
Q4 2018 Feb 12, 2019	BUY	$2.69 - $6.71 $104,318 - $260,213	38,780 Added 29.94%	168,310 $567,000
Q3 2018 Nov 13, 2018	BUY	$6.5 - $8.37 $350,707 - $451,603	53,955 Added 71.39%	129,530 $842,000
Q2 2018 Aug 02, 2018	BUY	$7.27 - $21.88 $549,430 - $1.65 Million	75,575 New	75,575 $579,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account